Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study - 02/11/21

Doi : 10.1016/S1470-2045(21)00402-2 
Fred Saad, ProfMD a, , Eleni Efstathiou, ProfMD b, Gerhardt Attard, ProfMD c, Thomas W Flaig, MD d, Fabio Franke, MD e, Oscar B Goodman, MD f, Stéphane Oudard, ProfMD g, Thomas Steuber, ProfMD h, Hiroyoshi Suzuki, ProfMD i, Daphne Wu, PhD j, Kesav Yeruva, PhD j, Peter De Porre, MD k, Sabine Brookman-May, ProfMD j, l, Susan Li, PhD m, Jinhui Li, PhD n, Shibu Thomas, PhD m, Katherine B Bevans, PhD o, Suneel D Mundle, PhD p, Sharon A McCarthy, BS p, Dana E Rathkopf, MD q
for the

ACIS Investigators*

  For the complete list of ACIS Investigators see Supplementary Material

a Centre Hospitalier de l’Université de Montréal, Université de Montréal, Montréal, QC, Canada 
b Athens Medical Center, Dept of GU Oncology, Athens, Greece 
c University College London, London, UK 
d University of Colorado Cancer Center, Aurora, CO, USA 
e ONCOSITE, Hospital Unimed Noroeste, Ijuí, Brazil 
f Comprehensive Cancer Centers of Nevada, US Oncology Network, Las Vegas, NV, USA 
g Georges Pompidou Hospital, University of Paris, Paris, France 
h Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany 
i Toho University Sakura Medical Center, Chiba, Japan 
j Janssen Research & Development, Los Angeles, CA, USA 
k Janssen Research & Development, Beerse, Belgium 
l Ludwig Maximilians University, Munich, Germany 
m Janssen Research & Development, Spring House, PA, USA 
n Janssen Research & Development, San Diego, CA, USA 
o Janssen Global Services, Horsham, PA, USA 
p Janssen Research & Development, Raritan, NJ, USA 
q Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, NY, USA 

* Correspondence to: Prof Fred Saad, Centre Hospitalier de l’Université de Montréal, Université de Montréal, Montréal, QC, Canada H2X 0A9 Centre Hospitalier de l’Université de Montréal Université de Montréal Montréal QC H2X 0A9 Canada



The majority of patients with metastatic castration-resistant prostate cancer (mCRPC) will have disease progression of a uniformly fatal disease. mCRPC is driven by both activated androgen receptors and elevated intratumoural androgens; however, the current standard of care is therapy that targets a single androgen signalling mechanism. We aimed to investigate the combination treatment using apalutamide plus abiraterone acetate, each of which suppresses the androgen signalling axis in a different way, versus standard care in mCRPC.


ACIS was a randomised, placebo-controlled, double-blind, phase 3 study done at 167 hospitals in 17 countries in the USA, Canada, Mexico, Europe, the Asia-Pacific region, Africa, and South America. We included chemotherapy-naive men (aged ≥18 years) with mCRPC who had not been previously treated with androgen biosynthesis signalling inhibitors and were receiving ongoing androgen deprivation therapy, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and a Brief Pain Inventory-Short Form question 3 (ie, worst pain in the past 24 h) score of 3 or lower. Patients were randomly assigned (1:1) via a centralised interactive web response system with a permuted block randomisation scheme (block size 4) to oral apalutamide 240 mg once daily plus oral abiraterone acetate 1000 mg once daily and oral prednisone 5 mg twice daily (apalutamide plus abiraterone–prednisone group) or placebo plus abiraterone acetate and prednisone (abiraterone–prednisone group), in 28-day treatment cycles. Randomisation was stratified by presence or absence of visceral metastases, ECOG performance status, and geographical region. Patients, the investigators, study team, and the sponsor were masked to group assignments. An independent data-monitoring committee continually monitored data to ensure ongoing patient safety, and reviewed efficacy data. The primary endpoint was radiographic progression-free survival assessed in the intention-to-treat population. Safety was reported for all patients who received at least one dose of study drug. This study is completed and no longer recruiting and is registered with ClinicalTrials.gov, number NCT02257736.


982 men were enrolled and randomly assigned from Dec 10, 2014 to Aug 30, 2016 (492 to apalutamide plus abiraterone–prednisone; 490 to abiraterone–prednisone). At the primary analysis (median follow-up 25·7 months [IQR 23·0–28·9]), median radiographic progression-free survival was 22·6 months (95% CI 19·4–27·4) in the apalutamide plus abiraterone–prednisone group versus 16·6 months (13·9–19·3) in the abiraterone–prednisone group (hazard ratio [HR] 0·69, 95% CI 0·58–0·83; p<0·0001). At the updated analysis (final analysis for overall survival; median follow-up 54·8 months [IQR 51·5–58·4]), median radiographic progression-free survival was 24·0 months (95% CI 19·7–27·5) versus 16·6 months (13·9–19·3; HR 0·70, 95% CI 0·60–0·83; p<0·0001). The most common grade 3–4 treatment-emergent adverse event was hypertension (82 [17%] of 490 patients receiving apalutamide plus abiraterone–prednisone and 49 [10%] of 489 receiving abiraterone–prednisone). Serious treatment-emergent adverse events occurred in 195 (40%) patients receiving apalutamide plus abiraterone–prednisone and 181 (37%) patients receiving abiraterone–prednisone. Drug-related treatment-emergent adverse events with fatal outcomes occurred in three (1%) patients in the apalutamide plus abiraterone–prednisone group (2 pulmonary embolism, 1 cardiac failure) and five (1%) patients in the abiraterone–prednisone group (1 cardiac failure and 1 cardiac arrest, 1 mesenteric arterial occlusion, 1 seizure, and 1 sudden death).


Despite the use of an active and established therapy as the comparator, apalutamide plus abiraterone–prednisone improved radiographic progression-free survival. Additional studies to identify subgroups of patients who might benefit the most from combination therapy are needed to further refine the treatment of mCRPC.


Janssen Research & Development.

Le texte complet de cet article est disponible en PDF.


© 2021  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer

    Export citations

  • Fichier

  • Contenu

Vol 22 - N° 11

P. 1541-1559 - novembre 2021 Retour au numéro
Article précédent Article précédent
  • Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial
  • Dean A Fennell, Sean Ewings, Christian Ottensmeier, Raffaele Califano, Gerard G Hanna, Kayleigh Hill, Sarah Danson, Nicola Steele, Mavis Nye, Lucy Johnson, Joanne Lord, Calley Middleton, Peter Szlosarek, Sam Chan, Aarti Gaba, Liz Darlison, Peter Wells-Jordan, Cathy Richards, Charlotte Poile, Jason F Lester, Gareth Griffiths, CONFIRM trial investigators, Gillian Price, Paul Shaw, Judith Cave, Jay Naik, Amy Ford, Tom Geldhart, Gairin Dancey, Dionysis Papadatos, Andy Polychronis, Petra Jankowska, Angela Scott, Jill Gardiner, Mathilda Cominos, Lynn Campbell, Carol MacGregor, Lois Mullholand, Meenali Chitnis, Gary Dougherty
| Article suivant Article suivant
  • Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study
  • Changhoon Yoo, Kyu-pyo Kim, Jae Ho Jeong, Ilhwan Kim, Myoung Joo Kang, Jaekyung Cheon, Byung Woog Kang, Hyewon Ryu, Ji Sung Lee, Kyung Won Kim, Ghassan K Abou-Alfa, Baek-Yeol Ryoo

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte

Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.

Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.